angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
== Diagnosis == Screening for muscle atrophy is limited by a lack of established diagnostic criteria, although many have been proposed. Diagnostic criteria for other conditions such as sarcopenia or cachexia can be used. These syndromes can also be identified with screening questionnaires. Muscle mass and changes can be quantified on imaging studies such as CT scans or Magnetic resonance imaging (MRI). Biomarkers such as urine urea can be used to roughly estimate muscle loss during circumstances of rapid muscle loss. Other biomarkers are currently under investigation but are not used in clinical practice.
==== 1900–1999 ==== Local Government (Scotland) Act 1975 (Local Authority Borrowing Limit) Order 1993 (S.I. 1993/1900) Nurses, Midwives and Health Visitors (Entry to Examinations and Training Requirements) Amendment Rules Approval Order 1993 (S.I. 1993/1901) Trade Union Reform and Employment Rights Act 1993 (Commencement No. 1 and Transitional Provisions) Order 1993 (S.I. 1993/1908) Trade Union Ballots and Elections (Independent Scrutineer Qualifications) Order 1993 (S.I. 1993/1909) Teddington Memorial Hospital National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/1932) Money Laundering Regulations 1993 (S.I. 1993/1933) Public Telecommunication System Designation (Scottish Hydro-Electric plc) Order 1993 (S.I. 1993/1934) Public Telecommunication System Designation (Energis Communications Limited) Order 1993 (S.I. 1993/1935) Education (Assisted Places) (Amendment) Regulations 1993 (S.I. 1993/1936) Education (Assisted Places) (Incidental Expenses) (Amendment) Regulations 1993 (S.I. 1993/1937) Education (Grants) (Music and Ballet Schools) (Amendment) Regulations 1993 (S.I. 1993/1938) Social Security (Disability Living Allowance) (Amendment) Regulations 1993 (S.I. 1993/1939) Food Protection (Emergency Prohibitions) (Paralytic Shellfish Poisoning) (No.4 and No.7) Orders 1993 Revocation Order 1993 (S.I. 1993/1940) Value Added Tax (General) (Amendment) (No. 6) Regulations 1993 (S.I. 1993/1941) Road Vehicles (Construction and Use) (Amendment) (No. 1) Regulations 1993 (S.I. 1993/1946) Tobacco Products Labelling (Safety) Amendment Regulations 1993 (S.I.
=== Similar species === In Europe, the spring-fruiting Amanita verna is a similar all-white species, as is the autumn-fruiting, white form of Amanita phalloides (deathcap). Both are equally poisonous. In their immature, button-mushroom stage, all these poisonous species could be mistaken for young, white-capped, edible mushrooms (Agaricus species), highlighting the danger of picking immature fruit bodies for food. In general, there are about 22 species that are considered destroying angels.
== Facial arrangements == The amino acids that make up a particular helix can be plotted on a helical wheel, a representation that illustrates the orientations of the constituent amino acids (see the article for leucine zipper for such a diagram). Often in globular proteins, as well as in specialized structures such as coiled-coils and leucine zippers, an α-helix will exhibit two "faces" – one containing predominantly hydrophobic amino acids oriented toward the interior of the protein, in the hydrophobic core, and one containing predominantly polar amino acids oriented toward the solvent-exposed surface of the protein. Changes in binding orientation also occur for facially-organized oligopeptides. This pattern is especially common in antimicrobial peptides, and many models have been devised to describe how this relates to their function. Common to many of them is that the hydrophobic face of the antimicrobial peptide forms pores in the plasma membrane after associating with the fatty chains at the membrane core.
=== Act 1 === W.P. Inman, a Confederate soldier wounded at the Battle of Petersburg, decides to desert from the Confederate Army and return home to Ada Monroe, his beloved who lives at Black Cove Farm, in North Carolina. Inman is aware of the Home Guard, which hunts down deserters from the Confederate Army. The leader of the local Home Guard is Teague, who resorts to such practices as burying deserters alive. On his journey home, Inman meets Solomon Veasey, whom he stops from committing murder. Meanwhile, Ada, once privileged, leads a life of material desperation. Ada meets Ruby, a mountain woman who teaches Ada about hunting and surviving. Inman encounters Veasey again, near a river whilst fleeing the Home Guard, and bargains with him for passage across the river. However, their vessel capsizes and the two drift down the river. The next morning, Lila and her three sisters see Inman and Veasey. Lila's husband drugs the two men before giving them up to the Home Guard. Inman and Veasey are put on a chain gang of deserters. Back at Black Cove Farm, Ruby finds her estranged father, Stobrod, a fiddler. Strobod is trying to steal food. Ruby wants nothing to do with her father, although he asserts that he has reformed his ways. Teague approaches, and Ruby hides her father. She later orders her father to stay away from her. Inman starts an insurrection among the chain gang. The guards shoot the entire chain gang, with a wounded Inman as the only survivor, chained to six dead prisoners. He relives the day he bid Ada farewell, when he thought that the war would last but six months.
Sources: en.wikipedia.org
=== Acting roles === Flay had a cameo appearance in the Disney Channel original movie Eddie's Million Dollar Cook-Off as the host of the cook-off. He appeared on the television game show Pyramid with fellow Iron Chef Mario Batali as the guest celebrities in an episode originally airing on November 18, 2003. He appeared as a judge on the CBS television show "Wickedly Perfect" during the 2004–05 season. He also appeared in the Law & Order: Special Victims Unit episode "Design", which originally aired on September 22, 2005. He had a small role as himself in the 2006 film East Broadway, in which his then-wife, Stephanie March, had a larger role. Jeopardy! featured a special "Throwdown with Bobby Flay" category during the March 12, 2008, episode, in which each of the clues featured Flay. He participated in the 2008 Taco Bell All-Star Legends and Celebrity Softball Game played at Yankee Stadium after the 2008 MLB All Star Game; Flay played for the National League. Flay is mentioned in the 2008 film Step Brothers in the "Derek comes for dinner" scene. In 2010, Flay was impersonated in the South Park cartoon episode "Crème Fraiche". In 2011, Flay had recurring appearances in the final season of Entourage as the boyfriend of Ari Gold's wife. In 2012, Flay appeared on Portlandia in a director's cut of the episode Brunch Village in which he showed director Jonathan Krisel how to make marionberry pancakes. Flay guest stars as himself on season two of the TV series Younger, which initially aired in 2016.
==== Insulin pump ==== An insulin pump delivers insulin subcutaneously. The insulin pump body itself can also contain the algorithm used in an AID system, or it can connect via Bluetooth with a separate mobile device (such as a phone) to send data and receive commands to adjust insulin delivery. Algorithm The algorithm for each AID system differs. In commercial systems (see below), little is known about the details of how the control algorithm works. In open source systems, the code and algorithm are openly available. In general, all algorithms do the same basic functionality of taking in CGM data and based on predicted glucose level's and the user's personal settings (for basal rates, insulin sensitivity, and carbohydrate ratio, for example) then recommends insulin dosing to help bring or maintain glucose levels in target range. Depending on the system, users may have the ability to adjust the target for the system, and may have different settings to ask the system to give more or less insulin in general.
Shaanxi Zhongbang Pharma-Tech Co., Ltd.-Supply of Epidermal Growth Factor EGF at the Human Protein Reference Database Archived 2005-05-03 at the Wayback Machine. Epidermal+growth+factor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) EGF model in BioModels database
== Process == The first step of the PEGylation is the suitable functionalization of the PEG polymer at one or both ends. PEGs that are activated at each end with the same reactive moiety are known as "homobifunctional", whereas if the functional groups present are different, then the PEG derivative is referred as "heterobifunctional" or "heterofunctional". The chemically active or activated derivatives of the PEG polymer are prepared to attach the PEG to the desired molecule. The overall PEGylation processes used to date for protein conjugation can be broadly classified into two types, namely a solution phase batch process and an on-column fed-batch process. The simple and commonly adopted batch process involves the mixing of reagents together in a suitable buffer solution, preferably at a temperature between 4 and 6 °C, followed by the separation and purification of the desired product using a suitable technique based on its physicochemical properties, including size exclusion chromatography (SEC), ion exchange chromatography (IEX), hydrophobic interaction chromatography (HIC) and membranes or aqueous two-phase systems (ATPS). The choice of the suitable functional group for the PEG derivative is based on the type of available reactive group on the molecule that will be coupled to the PEG. For proteins, typical reactive amino acids include lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, threonine and tyrosine.
Miraculin, is a glycoprotein extracted from Synsepalum dulcificum a berry which alters human tongue receptors to recognize sour foods as sweet. Variable surface glycoproteins allow the sleeping sickness Trypanosoma parasite to escape the immune response of the host. The viral spike of the human immunodeficiency virus is heavily glycosylated. Approximately half the mass of the spike is glycosylation and the glycans act to limit antibody recognition as the glycans are assembled by the host cell and so are largely 'self'. Over time, some patients can evolve antibodies to recognise the HIV glycans and almost all so-called 'broadly neutralising antibodies (bnAbs) recognise some glycans. This is possible mainly because the unusually high density of glycans hinders normal glycan maturation and they are therefore trapped in the premature, high-mannose, state. This provides a window for immune recognition. In addition, as these glycans are much less variable than the underlying protein, they have emerged as promising targets for vaccine design. P-glycoproteins are critical for antitumor research due to its ability block the effects of antitumor drugs. P-glycoprotein, or multidrug transporter (MDR1), is a type of ABC transporter that transports compounds out of cells. This transportation of compounds out of cells includes drugs made to be delivered to the cell, causing a decrease in drug effectiveness. Therefore, being able to inhibit this behavior would decrease P-glycoprotein interference in drug delivery, making this an important topic in drug discovery.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.